2 news items
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
CYTH
RFL
14 Jun 24
limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
CYTH
RFL
30 May 24
is a randomized, double-blind, placebo-controlled, parallel group, multicenter study designed to evaluate the safety, tolerability, and efficacy of 2,000 mg/kg
- Prev
- 1
- Next